PhaseWell RESEARCH

CASE STUDY / CNS

#1 enrolling site in a Phase II *Alzheimer's* trial.

A PhaseWell Research site randomized 16 patients against a goal of 8, more than any other of the study's 39 U.S. sites, working through a biomarker-gated funnel of 273 prescreens and 40 screenings.

ENROLLMENT

200%

Of site enrollment goal: 16 randomized vs. a target of 8

#1

Enrolling site in the study, of 39 U.S. sites

FUNNEL & QUALITY

273

Prescreens, narrowed to 40 screened and 16 randomized

24–48 hr

eCRF entry, with weekly data huddles

THE CHALLENGE

Most patients fail the biomarker gate, and most visits need a caregiver.

In an Alzheimer's trial, every randomized patient sits at the end of a long funnel, and most visits depend on both the patient and a caregiver.

High prescreen failure before biomarker confirmation

It took 273 prescreens and 40 screenings to randomize 16, with PET, MRI and p-tau labs confirming eligibility.

Caregiver requirements

Visits ran 1 to 6 hours, and most required a caregiver to attend.

Complex multi-vendor coordination

Across PET and MRI imaging, raters, infusion, eCOA and labs.

STUDY SNAPSHOT

SPONSOR	INDICATION	PHASE	SITE
Top 5 pharma	Early symptomatic Alzheimer's disease	Phase II	Renstar Medical Research, A PhaseWell Company

WHAT DROVE SUCCESS

A recruitment funnel built for volume, and the capacity to keep up with it.

Layered outreach

Site-sponsored memory screens, community talks, support groups, mobile pre-screening, neurology referrals and digital campaigns kept the top of the funnel full.

A database that delivered

The site's own patient database produced 9 of the 16 randomized patients. Chart review, a clinical connection vendor, digital ads and past patients supplied the rest.

Capacity for peak demand

Surge staffing and multiple screening teams and locations cleared bottlenecks, all under one unified quality program.

Certified, experienced raters

A dedicated rater pool kept cognitive assessments consistent across a high volume of visits.

Data huddles every week

A 24–48-hour eCRF entry SLA, weekly data huddles, rapid query turnaround, deviation control and internal auditing.

THE OUTCOME

What it meant for the sponsor.

> *High screeners, high enrollers, high-quality data.*
>
> STUDY SPONSOR

Twice the patients the sponsor planned for

The site doubled its goal and became the study's top enroller, randomizing 16 of 377 patients across 39 sites.

Families who stayed

Patient-centric scheduling and logistics support kept patients and caregivers engaged, for 88% retention.

Planning your next CNS study?

Let's talk about what our sites can do for your trial.

BD@PHASEWELL.COM